BioCryst Pharmaceuticals Inc BCRX:NASDAQ
RT Quote | Last NASDAQ LS, VOL From CTA | USD
After Hours: Last | 06/03/26 EDT8.16
-0.09 (-1.09%)
-0.09 (-1.09%)Volume
56,456
Close
8.25-0.09 (-1.08%)
-0.09 (-1.08%)Volume
4,171,881
52 week range
6.00 - 11.31
- Open8.33
- Day High8.47
- Day Low8.06
- Prev Close8.34
- 52 Week High11.31
- 52 Week High Date06/04/25
- 52 Week Low6.00
- 52 Week Low Date10/14/25
Latest On BioCryst Pharmaceuticals Inc
Key Stats
- Market Cap2.097B
- Shares Out254.16M
- 10 Day Average Volume3.94M
- Dividend-
- Dividend Yield-
- Beta0.57
Latest On BioCryst Pharmaceuticals Inc
KEY STATS
- Open8.33
- Day High8.47
- Day Low8.06
- Prev Close8.34
- 52 Week High11.31
- 52 Week High Date06/04/25
- 52 Week Low6.00
- 52 Week Low Date10/14/25
- Market Cap2.097B
- Shares Out254.16M
- 10 Day Average Volume3.94M
- Dividend-
- Dividend Yield-
- Beta0.57
RATIOS/PROFITABILITY
- EPS (TTM)-1.78
- P/E (TTM)-4.64
- Fwd P/E (NTM)35.71
- EBITDA (TTM)318.611M
- ROE (TTM)-1,925.37%
- Revenue (TTM)885.716M
- Gross Margin (TTM)97.76%
- Net Margin (TTM)-51.71%
- Debt To Equity (MRQ)-152.59%
EVENTS
- Earnings Date08/03/2026(est)
- Ex Div Date-
- Div Amount-
- Split Date-
- Split Factor-
Content From Our Affiliates
Related Video
watch now
Profile
MOREBioCryst Pharmaceuticals, Inc. discovers oral and small-molecule medicines that treat rare diseases in which unmet medical needs exist and an enzyme plays the key role in the biological pathway of the disease. ORLADEYO (berotralstat) is an oral, once-daily therapy that is approved in the United States, the European Union, Japan, and the United Kingdom for the prevention of hereditary angioedema attacks in adults and pediatric patients 12 years and older. The Company has...
Nancy Hutson Ph.D.
Independent Chairman of the Board
Charles Gayer
President, Chief Executive Officer, Director
Babar Ghias
Chief Financial Officer, Head of Corporate Development
Address
4505 Emperor Blvd Ste 200
Durham, NC
27703-8457
United States